1 Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or 2 vector-based COVID-19 vaccinations

Henning Jacobsen^{#,1}, Monika Strengert^{#,2,3}, Henrike Maaß^{*,1}, Mario Alberto Ynga Durand^{*,1}, 3 Barbora Kessel², Manuela Harries², Ulfert Rand¹, Leila Abassi¹, Yeonsu Kim¹, Tatjana 4 Lüddecke¹, Pilar Hernandez², Julia Ortmann², Jana-Kristin Heise², Stefanie Castell², Daniela 5 Gornyk², Stephan Glöckner², Vanessa Melhorn², Berit Lange^{2,5}, Alex Dulovic⁴, Julia Häring⁴, 6 Daniel Junker⁴, Nicole Schneiderhan-Marra⁴, Markus Hoffmann^{6,7}, Stefan Pöhlmann^{6,7}, Gérard 7 Krause^{2,3,5,§}. Luka Cicin-Sain^{1,5,8,§} 8 9 1 Helmholtz Centre for Infection Research, Department of Viral Immunology, Braunschweig, 10 Germany 2 Helmholtz Centre for Infection Research, Department of Epidemiology Braunschweig, 11 12 Germanv 13 3 TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture of the Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, 14 15 Germany 16 4 NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, 17 Germany 18 5 German Centre for Infection Research (DZIF), partner site Hannover-Braunschweig, Germany 6 Deutsches Primatenzentrum, Leibniz-Institut für Primatenforschung, Göttingen, Germany 19 7 Faculty of Biology and Psychology, Georg-August-University Göttingen, Germany 20 8 Centre for Individualized Infection Medicine (CIIM), a joint venture of Helmholtz Centre for 21 Infection Research and Medical School Hannover, Germany 22 23 # (first authors), * (second authors), § (corresponding authors): these authors contributed 24 25 equally. 26 27 Corresponding authors contact details: Luka Cicin-Sain, Phone number: +49 (0)53161814616, Email address: 28 luka.cicin-29 sain@helmholtz-hzi.de, Postal address: Inhoffenstraße 7, 38124 Braunschweig, Germany. 30

Abstract 32

- Background: SARS-CoV-2 variants accumulating immune escape mutations provide a 33
- 34 significant risk to vaccine-induced protection. The novel variant of concern Omicron (B.1.1.529) has to date the largest number of amino acid alterations in its Spike protein. Thus, it may
- 35 efficiently escape recognition by neutralizing antibodies, allowing breakthrough infections in
- 36
- convalescent and vaccinated individuals. 37
- 38 Aims: We analysed neutralization activity of all mRNA-, vector- or heterologous immunization 39 schemes currently approved in Europe at peak response and in a longitudinal follow-up with BNT162b2 vaccinees to define immune escape potential of the Omicron VoC. 40
- Methods: We tested sera by in vitro pseudotype particle neutralization assay towards SARS-41 CoV-2 B.1, Omicron, Beta and Delta Spike proteins. 42
- Results: All vaccines apart from Ad26.CoV2.S showed high levels of responder rates (93-100%) 43
- 44 towards SARS-CoV-2 wild-type, but some reductions in neutralizing Beta and Delta VoC
- 45 pseudotypes. The novel Omicron variant had the biggest impact, both in terms of response
- 46 rates and neutralization titres among responders. Only mRNA-1273 showed a 100% response
- 47 rate to Omicron and induced the highest titres of neutralizing antibodies, followed by
- heterologous prime-boost approaches. Homologous BNT162b2 vaccination or vector-based 48
- formulations with AZD1222 or Ad26.CoV2.S performed less well with peak responder rates of 49 50 33%, 50% and 9%, respectively. However, Omicron responder rates in BNT162b2 recipients
- 51 were maintained in our six month longitudinal follow-up and even slightly increased to 47%,
- 52 indicating Omicron cross-protection is maintained over time.
- 53 Conclusions: Our data strongly argues for urgent booster doses particularly for those who were
- previously vaccinated with BNT162b2 or a vector-based immunization scheme. 54

55 **Keywords**

- 56 SARS-CoV-2, Omicron, B.1.1.529, variants of concern, protective immunity, neutralization, 57 COVID-19 vaccination
- 58

It is made available under a CC-BY-NC 4.0 International license .

60 Introduction

Since its emergence in late 2019, SARS-CoV-2 has caused a pandemic with more than 270 61 million confirmed infections and more than 5 million deaths[1]. While a series of vaccines have 62 63 been developed with unprecedented speed and were successfully deployed to limit the burden 64 of COVID-19, it became quickly apparent that novel SARS-CoV-2 variants had evolved, mainly 65 in areas of high virus prevalence. Those have accumulated mutations in the surface-exposed Spike protein, which increase virus transmissibility or promote evasion from the host immune 66 67 response[2-4]. Immune escape was most pronounced in SARS-CoV-2 variants Beta (B.1.351) and the currently globally dominating Delta (B.1.617.2), at least until recently. However, the 68 69 November 2021 emergence of the variant B.1.1.529 (Omicron) in South Africa has raised strong 70 concerns as its unusually high number of amino acid alterations in the Spike protein will likely 71 contribute to an increased reinfection risk or breakthrough infections following vaccination[5]. By 72 now, a series of studies using samples from convalescent and vaccinated individuals have 73 addressed the impact of Omicron on vaccination or infection-induced antibody neutralization, 74 using either live-, pseudovirus neutralization or in vitro binding assays[6-14]. These studies have shown clear losses of neutralization capacity against the Omicron variant but did not 75 comprehensively address antibody responses in various vaccination regimens or over time. In 76 77 contrast, we provide here a comprehensive assessment of vaccination schemes approved in 78 the European Union and the UK, using an Omicron, Beta, Delta or wild-type (B.1) pseudo-79 neutralization assay at peak response after approximately four weeks and in a longitudinal six 80 month follow-up for BNT162b2.

81 Methods

82 Sample collection

Serum samples analyzed in this study originate from vaccinated participants of the multi-local 83 84 and serial cross-sectional prevalence study on antibodies against SARS-CoV-2 in Germany (MuSPAD) study, a population-based SARS-CoV-2 seroprevalence study in eight regions of 85 Germany from July 2020 to August 2021. The study was approved by the Ethics Committee of 86 the Hannover Medical School (9086_BO_S_2020) and was in line with the Declaration of 87 88 Helsinki. Briefly, MuSPAD is a successive cross-sectional study where certain locations were sampled longitudinally within a 3-4 month interval [15]. Recruitment of eligible participants (>18 89 years) was based on age- and sex-stratified random sampling with information provided by the 90 respective local residents' registration offices. Basic sociodemographic data and information on 91 pre-existing medical conditions including a previous SARS-CoV-2 infection or vaccination are 92 93 self-reported and were documented with eResearch system PIA (Prospective Monitoring and Management-App) at the study center. Peripheral blood was obtained by venipuncture using a 94 95 serum gel S-Monovette (Sarstedt) and further processed according to the manufacturer's 96 instructions. Serum was then aliquoted at the German Red Cross Institute of Transfusion 97 Medicine and Immunohematology and transported on dry ice to the Hannover Unified Biobank 98 for long-term storage.

For this study, we selected 82 samples from the available sample pool to contain mRNA, vector-99 100 and heterologous immunization schemes at peak response and if available for a paired six month follow-up with BNT162b2 only. None of the donors reported a positive SARS-CoV-2 101 102 antigen or PCR test result and were non-reactive for nucleocapsid-specific IgG, excluding 103 confounders due to infections superposed on vaccination in our cohort. Vaccination details with 104 basic sociodemographic information and pre-existing conditions such as hypertension, 105 cardiovascular disease, diabetes, lung disease, immunosuppression or cancer of participants 106 are provided in Table 1 and Supplementary Table S1. As controls, the first WHO International 107 Standard for human anti-SARS-CoV-2 immunoglobulin (code: 20/136) from the National 108 Institute for Biological Standards and Control (NIBSC) or pre-pandemic sera samples from an anonymized Hepatitis A and Influenza virus vaccination response study at the Helmholtz Centre 109 for Infection Research in 2014 (Hannover Medical School Ethics Committee approval number 110 2198-2021) were used. 111

112 Cell culture

¹¹³ Vero E6 (ATCC CRL-1586), and 293T (DSMZ ACC-635) were maintained in DMEM medium ¹¹⁴ supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin and ¹¹⁵ 100 μ g/ml streptomycin at 37 °C in a 5% CO₂ atmosphere. All cell lines used within this study ¹¹⁶ were below a passage of 50 and were regularly checked for mycoplasma contamination.

117 Transfection of 293T cells was performed using calcium-phosphate.

118 Plasmids

Plasmids encoding SARS-CoV-2 Spike B.1 (human codon optimized, 18 amino acid truncation at C-terminus) and SARS-CoV-2 spike of Beta (B.1.351) and Delta (B.1.617.2) have been previously reported [16-18]. The expression vector for SARS-CoV-2 Spike of Omicron (based on isolate hCoV-19/Botswana/R40B58_BHP_3321001245/2021; GISAID Accession ID: EPI_ISL_6640919) was generated by Gibson assembly [13]. An overview of mutations is present in Supplementary Table S2. All plasmids were sequence-confirmed by Sanger sequencing prior to use.

126 Pseudotyping

Generation of rhabdoviral pseudotypes harboring SARS-CoV-2 Spike proteins was performed 127 as described[19]. In brief, 293T cells were transfected with pCG1 plasmids expressing different 128 SARS-CoV-2 Spike proteins, using calcium-phosphate. 24 h post transfection, cells were 129 130 infected with a replication-deficient reporter VSV-G (VSV+∆G-Fluc) at an MOI of 3 for 1 h at 37 °C [20]. Cells were washed once with PBS and medium containing anti-VSV-G antibody (culture 131 supernatant from L1-hybridoma cells) was added to neutralize residual input virus. The cell 132 133 culture supernatant was harvested after 16 hours, and cellular debris was removed by 134 centrifugation at 2.000 g for 5 min at 4 °C. Aliquots were stored at -80°C until use.

135 Neutralization assay

For pseudovirus neutralization, serum samples and controls were heat-inactivated at 56 °C for 30 min. Thawed samples and controls were stored at 4°C for no longer than 48 hours, prior to use. In a 96-well microtiter plate, serum samples were 2-fold serially diluted in cell culture

medium (DMEM, 5 % FBS, 1% P/S, 1% L-Glu) with a dilution range of 1:10 to 1:5120. Pre-139 140 diluted samples were incubated with an equal volume of Spike protein-bearing viral particles (approx. 200 - 500 ffu/well) at 37 °C for 1 h. After incubation, the sample-virus mixture was 141 142 transferred to VeroE6 cells at 100% confluence which were seeded the day before. Cells were 143 incubated at 37 °C for 24±2 h and infected cells were visualized using an IncuCyte S3 (Sartorius) performing whole-well scans (4x) in phase contrast and green fluorescence settings. 144 Automated segmentation and fluorescent foci counting was performed using the IncuCyte GUI 145 146 software (versions 2019B Rev1 and 2021B) Raw data were plotted in GraphPad prism (v8) and FRNT₅₀ was calculated with a variable slope, four parameter regression analysis. Non-147 148 responders were defined as subjects with undetectable neutralization titers at an initial serum dilution of 1:10. FRNT₅₀ values of those individuals were arbitrarily set to 1. All experiments 149 150 were performed with internal standard controls (pool of all tested sera), negative controls and virus-only controls to assess the nominal virus input for every single measurement. 151

152 Data analysis and statistics

Initial results collation and matching to metadata was done in Excel 2016 and R 4.1.0. Graphs 153 and statistical calculations were performed using GraphPad Prism version 9.0.2 for Windows 154 155 (GraphPad Software). For analysis of neutralization assay results, a Shapiro-Wilk test was used 156 to determine normality. Focus Reduction Neutralization titre with a 50% neutralization cut-off (FRNT₅₀) was calculated using a four-parameter regression analysis function. FRNT₅₀ values 157 from non-responders were set to 1.0 for graphical presentation only. A non-parametric 158 Friedman's test followed by Dunn's multiple comparison analysis was used to compare 159 160 neutralization results to different viruses in a pair-wise manner for matched samples. Two-tailed 161 Wilcoxon matched-pairs signed rank test was used to compare neutralization of longitudinal results. A p-value of less than 0.05 was considered statistically significant. 162

163 Results

164 Neutralization responses towards B.1, B.1.1.529, B.1.351, and B.1.617.2 Spike-expressing rhabdoviral pseudotypes were analysed in 82 serum samples from individuals vaccinated with 165 either a single dose of Ad26.COV2.S, homologous two-dose BNT162b2, mRNA-1273 or 166 167 AZD1222 vaccination, or heterologous AZD1222-BNT162b2 or AZD1222-mRNA-1273 168 vaccination at peak response, approximately four weeks after the last dose. The WHO international standard serum showed detectable neutralization against all variants including 169 Omicron (Supplementary Table S3), showing excellent sensitivity of our assay, compared to 170 previous studies [21]. Pre-pandemic control sera (n=4) showed no measurable neutralization 171 levels (Supplementary Table S3). While neutralization potency towards Beta VoC pseudotypes 172 were clearly reduced for all vaccination schemes, Omicron had the strongest effect across all 173 samples tested (Fig. 1). Vaccination with vector-based Ad26.CoV2.S performed least well (Fig. 174 175 1a), with only 73% responders against the B.1 variant, 18% classified as responders for the 176 Beta VoC and 9% for Omicron. Homologous vaccination with either AZD1222 or BNT162b2 performed better against Omicron, with 50% or 33% responders, respectively (Fig. 1b, 1c). 177 178 Heterologous immunization with these two vaccines (AZD1222-BNT162b2) showed a response 179 rate of 80% (Fig. 1d). Heterologous vaccination with AZD1222-mRNA-1273 had a similar 180 response rate of 82% (Fig. 1e), but homologous immunization with mRNA-1273 had the highest

It is made available under a CC-BY-NC 4.0 International license .

Omicron response rate of 100% (Fig. 1f). Non-responders were defined as subjects with 181 182 undetectable neutralization titers at an initial serum dilution of 1:10. Non-parametrical statistical comparisons showed a highly significant reduction in serum titres when Omicron neutralization 183 184 was compared to B.1 for all vaccination schemes (Fig 1b-e).). There was no tendency of age, 185 sex, or pre-existing medical conditions to modify the responder status against Omicron in our cohort (Supplementary Table S3). To assess the impact of immune escape with more detail, we 186 187 focused on the responders and compared geometric means of their FRNT₅₀ titres (GMT). Importantly, fold-changes for groups that included non-responders are not provided in Fig. 1, 188 189 because this would lead to highly artificial results and possibly over-interpretation. We therefore 190 present the percentage of responders as primary outcome and provide fold-changes of GMT where calculation is reasonable (100% responders in both arms). Furthermore, for each 191 vaccination regimen, we defined the responder subgroups (excluding non-responders in either 192 193 group) and compared the fold-reduction for titres that could be quantified (see Table 2). In these subsets, we observed an approximate 15-fold reduction in GMT for most vaccinations, except 194 195 BNT162b2, where the reduction was 28-fold at peak responses. This was consistent with the 196 high frequency of non-responders in this subset, additionally arguing for weaker protection 197 against the Omicron variant in this cohort.

Since BNT162b2 is very commonly used, we tested the neutralization potency in BNT162b2 198 recipients at approximately six months post immunization as well. Similar to the peak 199 200 responses, we observed a significantly weaker neutralization of the Omicron compared to the 201 B.1 pseudotype and only 47% responders against the newly emerging VoC (Fig. 2a). Beta 202 neutralization was slightly reduced, whereas Delta neutralization was at same levels as B.1 at 203 the late time point (Fig. 2a). To understand the longitudinal dynamic of humoral immunity, we 204 used paired sera from BNT162b2 vaccine recipients at four weeks (already shown in Fig. 1c) 205 and at six months post second dose which allowed us to compare intra-individual titre changes over time (Fig. 2b-d). While the neutralization of B.1 (Fig. 2b) and of the Delta VoC (Fig. 2d) 206 207 decreased significantly over time, the time dependent reduction was less pronounced for the Beta (Fig 2c) or the Omicron VoC (Fig. 2e). Moreover, all Omicron responders identified early 208 209 after vaccination had still detectable neutralizing capacity at the late time points and two 210 additional responders were identified in the late phase only (Fig. 2e). Therefore, the differences 211 in neutralization titres between B.1 and Omicron responders were less pronounced at late time 212 points than at peak response (Table 2).

In sum, homologous mRNA-1273 vaccination resulted in the highest responder rate,
Ad26.CoV2.S in the lowest, and longitudinal follow-up showed that Omicron responses, while
reduced, seem rather durable if present in the first place.

216 Discussion

We provide a comprehensive overview of neutralization responses from all currently approved COVID-19 vaccination schemes in the European Union and the UK not only towards the Omicron VoC, but also towards Beta and Delta VoC compared to the parental strain B.1. We expand on previous findings [11, 12] that neutralization towards Omicron is particular poor after vaccination with vector-based formulations even within the peak phase shortly after vaccination. Also consistent with other reports [13, 14], we observed a very low cross-neutralization in

It is made available under a CC-BY-NC 4.0 International license .

223 BNT162b2 recipients. While our BNT162b2 samples had rather low neutralization titres overall, 224 there was no signal this was due to clear differences in group, age or comorbidities. Considering our relatively small sample size, it is however possible that this low overall response in the 225 226 BNT162b2 group was a spurious observation. Nevertheless, the samples showing any cross-227 neutralizing responses early on remained responsive to Omicron six months later. Notably, all mRNA-1273 recipients and 80% of those receiving any heterologous vaccination showed a 228 229 detectable neutralization against Omicron in our analysis. It is not clear, why these vaccination 230 protocols were more efficient against the Omicron pseudotype than BNT162b2, but it is 231 indicative that the baseline neutralization against the B.1 pseudotype was stronger in all of them 232 in our sample cohorts.

The detectable responsiveness to the Omicron pseudotype in all mRNA-1273 recipients differed 233 234 from previous reports where usually several samples showed no measurable neutralization against Omicron [12, 14, 22]. This might be due to sampling differences, a result of increased 235 236 sensitivity in our assay, or both. We chose responder rates as primary outcome because this is 237 a less biased expression than fold changes if titres from non-responsive individuals are 238 calculated. For the same reason, we used a non-parametric assay to evaluate differences, 239 allowing us to include samples that were below detection threshold, but obviously very low in 240 titre. Fold changes were calculated separately on a subset of samples that showed detectable 241 titres in all circumstances. We observed an approximately 15-fold reduction in most vaccination 242 regimens except BNT162b2, adding evidence that Omicron cross-neutralization was impaired in 243 this cohort. While sample numbers in our cohort are low, they are comparable to the majority of other studies to date and are well-matched on age and sex. 244

Following current recommendations, a booster vaccination is generally advised after six months. Considering our results, booster vaccination might already be advised at earlier stages, especially for risk groups in the absence of a precise and clinically relevant correlate of protection.

Overall, we provide further evidence that that amino acid mutations accumulated in the B.1.1.529 Spike protein serve to escape vaccine-induced protection. In the absence of conclusive data on infectivity and disease severity, development of adapted second generation vaccinations, booster doses and careful monitoring of future variants of concern appears warranted.

254 Funding

255 This work was financially supported by the Initiative and Networking Fund of the Helmholtz 256 Association of German Research Centres through projects "Virological and immunological determinants of COVID-19 pathogenesis - lessons to get prepared for future pandemics (KA1-257 258 Co-02 "COVIPA") to LCS and grant number SO-96 to GK, by the Deutsche 259 Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy - EXC 2155 "RESIST" - Project ID 39087428 to LCS, and intramural funds of the 260 Helmholtz Centre for Infection Research. SP was supported by BMBF (01KI2006D, 261 01KI20328A, 01KX2021), the Ministry for Science and Culture of Lower Saxony (14-76103-184, 262 MWK HZI COVID-19) and the German Research Foundation (DFG; PO 716/11-1, PO 716/14-263 264 1).

It is made available under a CC-BY-NC 4.0 International license .

265 **Declaration of Interest**

NSM was a speaker at Luminex user meetings in the past. The Natural and Medical Sciences Institute at the University of Tübingen is involved in applied research projects as a fee for services with the Luminex Corporation. The other authors declare no competing interest.

269 Acknowledgments

We want to thank again all parties involved in any capacity in making MuSPAD happen. Most of all the study participants for their willingness and commitment to make this study possible and all colleagues at the HZI, the Hannover Unified Biobank and the DRK Institute of Transfusion Medicine and Immunohematology who contributed to project administration, organization and sample processing. We thank Daniela Lenz, Ayse Barut, Inge Hollatz-Rangosch and Fawad Khan for excellent technical assistance during this study.

276 Author contribution

277 MS, HJ, LCS conceived the study. MS, GK, BL, SC, NSM, SP and LCS procured funding. GK,

BL, MS, MaH and DG designed the population-based cohort this study is based on. HJ, MS and

LCS designed the experiments. HJ, HM, MYD, UR, LA, YK and TL performed the experiments.

280 MHa, BK, MS, JH, MYD and HM performed data analysis. MS, HJ, HM, MYD generated figures

and tables. MS, BK, HJ, LCS verified the underlying data. MHo, SP provided reagents. AD, DJ, JH, MS, BK, PH, BL, SC, MHa, DG, SG, JKH, VM were involved in sample or data collection

and project administration. MS, HJ, LCS wrote the manuscript. All authors critically reviewed

and approved the final manuscript.

285 Data Sharing Statement

Raw data is provided with the manuscript. Additional data is available upon request from the corresponding authors.

288

It is made available under a CC-BY-NC 4.0 International license .

290 Figures



²⁹¹ 292

Figure 1. Impact of SARS-CoV-2 vaccination schemes on neutralization response towards Omicron (B.1.1.529) variant.

295 Vaccination-induced neutralization potency against Omicron (B.1.1.529), Beta (B. 1.351), Delta 296 (B.1.617.2) or Wuhan (B.1) pseudotypes was measured in individuals who received a vector-297 based vaccination with single dose Ad26.CoV2.S (n=11, a), two doses of AZD1222 (n=14, b), two doses of mRNA vaccine BNT162b2 (n=15, c), a heterologous two-dose vaccination with 298 299 AZD1222-BNT162b2 (n=15, d) or AZD1222-mRNA-1273 (n=11, e), or two doses of mRNA vaccine mRNA-1273 (n=16, f) 21 to 61 days after the last dose. FRNT₅₀ data is expressed for 300 each serum sample, bold horizontal lines and whiskers are geometric means with 95% CI. 301 Interconnecting lines represent sample data from the same donor. Non-neutralizing sample 302 303 values were arbitrarily set to 1 for presentation purposes, indicated by a dashed line. Fold

It is made available under a CC-BY-NC 4.0 International license .

change in neutralization potency between SARS-CoV-2 wild-type and VoC pseudotypes is 304 305 shown below p-values. Percentage (%) responder rates and FRNT₅₀ geometric mean titres (GMT) per SARS-CoV-2 pseudotype are shown above the individual measurements. Fold 306 307 change in neutralization potency and GMTs for SARS-CoV-2 pseudotypes are only calculated 308 for groups where all samples had a detectable neutralizing activity, or else non-applicable (na) 309 is stated. Time between sampling and full vaccination in days is displayed as mean and SD below the vaccination scheme. Statistical analysis was performed by paired non-parametric 310 311 Friedman's test followed by a Dunn's multiple comparison analysis. Statistical significance was defined by a value of *<0.05; ** <0.01; ***<0.001; ****<0.0001. 312 313

It is made available under a CC-BY-NC 4.0 International license .



314 315

Figure 2. Longitudinal BNT162b2 neutralization response towards SARS-CoV-2 VoC Omicron (B.1.1.529).

Neutralization capacity towards SARS-CoV-2 Omicron (B.1.1.529), Beta (B. 1.351), Delta (B.1.617.2) or Wuhan (B.1) pseudotypes was analysed approximately six months after a two-

It is made available under a CC-BY-NC 4.0 International license .

320 dose BNT162b2 vaccination (n=15, a). Neutralization kinetic of paired longitudinal samples 321 towards SARS-CoV-2 B.1 (b), Beta (c), Delta (d) and Omicron (e) pseudotypes is shown between T1 (n=15; mean (SD) Δ T after last dose: 28.3 (4.3)) and T2 (n=15; mean (SD) Δ T after 322 323 last dose: 173.6 (11.4)). Peak neutralization responses of BNT162b2-vaccinated individuals 324 from Figure 1c are displayed for clarity and comparison (b-e). FRNT₅₀ data is expressed for each serum sample, bold horizontal lines and whiskers are geometric means with 95% CI. 325 Interconnecting lines represent sample data from the same donor (a-e). Non-neutralizing 326 327 samples were arbitrarily set to 1 for presentation purposes, indicated by a dashed line. Fold change in neutralization potency between SARS-CoV-2 wild-type and VoC pseudotypes is 328 329 shown below p-values. Percentage (%) responder rates and FRNT₅₀ geometric mean titres (GMT) per SARS-CoV-2 pseudotype are shown above the individual measurements. Fold 330 change in neutralization potency and GMTs for SARS-CoV-2 pseudotypes are only calculated 331 for groups where all samples had a detectable neutralizing activity, or else non-applicable (na) 332 is stated. Statistical analysis was performed by paired non-parametric Friedman's test followed 333 by a Dunn's multiple comparison analysis (a) or a by two-tailed Wilcoxon matched-pairs signed 334 335 rank test. Statistical significance was defined by a value of *<0.05; ** <0.01; ***<0.001; 336 ****<0.0001. 337

It is made available under a CC-BY-NC 4.0 International license .

339 **Table 1. Sample characteristics** (na: not applicable)

340

Sample cohort	ΔT (days) post-complete	ΔT (days) between	Age (years),	Sex (n, %)	
(n)	(n) vaccination doses med (mean, SD) (mean, SD)		median (IQR)	Female	Male
two-dose BNT162b2 T1* (15)	28.3 (4.8)	21.2 (1.2)	50 (39-56)	12 (80.0)	2 (20 0)
two-dose BNT162b2 T2* (15)	173.6 (11.4)	21.3 (1.2)	50 (40-57)	12 (00.0)	3 (20.0)
two-dose mRNA-1273 (16)	28.5 (4.2)	32.0 (6.1)	56 (54-68)	11 (68.8)	5 (31.2)
first dose AZD1222, second dose mRNA-1273 (11)	28.2 (4.4)	65.4 (21.6)	68 (65-73)	7 (63.7)	4 (36.4)
first dose AZD1222, second dose BNT162b2 (15)	26.0 (4.1)	76.2 (7.7)	67 (65-69)	4 (26.7)	11 (73.4)
two-dose AZD1222 (14)	27.1 (1.2)	77.6 (1.8)	65 (63-69)	7 (50.0)	7 (50.0)
one-dose Ad26.CoV2.S (11)	55.3 (5.4)	na	61 (58-63)	7 (63.6)	4 (36.4)

* Two-dose BNT162b2 T1 and two-dose BNT162b2 T2* are paired longitudinal samples.

It is made available under a CC-BY-NC 4.0 International license .

Table 2. Geometric means of responses and fold changes in Omicron responder subsets 342

Vaccination	GMT (95% CI) of paired <u>responders</u>					
regimen	B.1	Beta	Delta	Omicron		
two-dose mRNA-1273	526.0 (368.1-751.5)	119.6 (70.7-202.5)	481.5 (70.7-202.5)	33.2 (21.2-52.2)		
first dose AZD1222, second dose BNT162b2 first dose	902.8 (572.0-1425.0)	173.9 (109.0-277.5)	173.9 (109.0-277.5)	61.5 (44.0-85.9)		
AZD1222, second dose mRNA-1273	1323.0 (740.6-2363.0)	368.9 (156.9-867.3)	923.8 (418.5-2039.0)	75.6 (41.2-138.9)		
two-dose AZD1222	186.4 (91.2-381.3)	46.4 (20.8-103.5)	95.3 (41.5-232.9)	14.6 (7.0-30.5)		
one-dose Ad26.CoV2.S*	na	na	na	na		
two-dose BNT162b2 T1 **	393.0 (213.5-723.6)	56.6 (14.3-223.5)	503.5 (275.2-921.0)	13.7 (7.8-24.1)		
two-dose BNT162b2 T2 **	82.6 (60.1-113.6)	31.3 (16.8-58.2)	85.7 (51.4-142.7)	10.9 (7.3-16.5)		
Vaccination regimen	Fold-change in GMT of paired <u>responders</u>					
	B.1	Beta	Delta	Omicron		
two-dose mRNA-1273	-	-4.4	-1.1	-15.8		
first dose AZD1222, second dose BNT162b2	-	-5.2	-1.6	-14.7		
first dose AZD1222, second dose mRNA-1273	-	-3.6	-1.4	-17.5		
two-dose AZD1222	-	-4.0	-1.9	-12.8		
one-dose Ad26.CoV2.S*	-	na	na	na		
two-dose BNT162b2 T1 **	-	-6.9	-0.8	-28.7		
two-dose BNT162b2 T2	-	-2.6	-1.0	-7.5		

* Only one subject showed detectable neutralization titers in the Omicron assay.

** Two-dose BNT162b2 T1 and two-dose BNT162b2 T2 are paired longitudinal samples.

It is made available under a CC-BY-NC 4.0 International license .

343

344 **References**

345	1. WHO. WHO Coronavirus (COVID-19) Dashboard 2021 [Available from: <u>https://covid19.who.int/</u> .
346	2. Altmann DM, Boyton RJ, Beale R. Immunity to SARS-CoV-2 variants of concern. Science.
347	2021;371(6534):1103-4.
348	3. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of
349	Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385(7):585-94.
350	4. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The biological and
351	clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2021;22(12):757-73.
352	5. WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern 2021 [Available
353	from: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-
354	<u>variant-of-concern</u> .
355	6. Zhang L, Li Q, Liang Z, Li T, Liu S, Cui Q, et al. The significant immune escape of pseudotyped
356	SARS-CoV-2 Variant Omicron. Emerg Microbes Infect. 2021:1-11.
357	7. Cele S, Jackson L, Khan K, Khoury DS, Moyo-Gwete T, Tegally H, et al. SARS-CoV-2 Omicron has
358	extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for
359	infection. medRxiv. 2021.
360	8. Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, et al. Reduced neutralisation of
361	SARS-COV-2 Omicron-B. 1.1. 529 variant by post-immunisation serum. medRxiv. 2021.
362	9. Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, et al. Reduced Neutralization of
363	SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies. medRxiv. 2021.
364	10. Schubert M, Bertoglio F, Steinke S, Heine PA, Ynga-Durand MA, Zuo F, et al. Human serum from
365	SARS-CoV-2 vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2
366	Omicron variant. medRxiv. 2021.
367	11. Schmidt F, Muecksch F, Weisblum Y, Silva JD, Bednarski E, Cho A, et al. Plasma neutralization
368	properties of the SARS-CoV-2 Omicron variant. medRxiv. 2021.
369	12. Rossler A, Riepler L, Bante D, Laer DV, Kimpel J. SARS-CoV-2 B.1.1.529 variant (Omicron) evades
370	neutralization by sera from vaccinated and convalescent individuals. medRxiv, 2021.
371	13. Hoffmann M, Kruger N, Schulz S, Cossmann A, Rocha C, Kempf A, et al. The Omicron Variant is
372	nighly resistant against antibody-mediated neutralization – implications for control of the COVID-19
3/3	pandemic. DioRXIV. 2021.
374	14. Garcia-Beitran WF, St. Denis KJ, Hoeizemer A, Lam EC, Nitido AD, Sneenan MiL, et al. MKNA-
375	madbyly 2021
570 277	11eunxiv. 2021. 15 — Corput D. Harrigs M. Glöckpor S. Strongert M. Kerrinnes T. Heise J.K. et al. SARS CoV.2
378	seronrevalence in Germany, Deutsches Ärzteblatt international, 2021
370	16 Hoffmann M. Zhang L. Kruger N. Graichen L. Kleine Weber H. Hofmann Winkler H. et al. SARS
380	CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell Ren
381	
382	17 Hoffmann M Arora P Gross R Seidel A Hornich BE Hahn AS et al. SARS-CoV-2 variants B 1 351
383	and P 1 escape from neutralizing antibodies. Cell 2021;184(9):2384-93 e12
384	18. Brinkmann C. Hoffmann M. Lubke A. Nehlmeier I. Kramer-Kuhl A. Winkler M. et al. The
385	glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive
386	cells. PLoS One. 2017;12(12):e0189073.
387	19. Kleine-Weber H, Elzavat MT, Wang L, Graham BS. Muller MA. Drosten C. et al. Mutations in the
388	Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase
389	Resistance to Antibody-Mediated Neutralization. J Virol. 2019;93(2).

It is made available under a CC-BY-NC 4.0 International license .

- 390 20. Berger Rentsch M, Zimmer G. A vesicular stomatitis virus replicon-based bioassay for the rapid 391 and sensitive determination of multi-species type I interferon. PLoS One. 2011;6(10):e25858.
- 392 21. Aggarwal A, Stella AO, Walker G, Akerman A, Milogiannakis V, Brilot F, et al. SARS-CoV-2
- 393 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to 394 viral variants of concern. medRxiv. 2021:2021.12.14.21267772.
- 22. Doria-Rose NA, Shen X, Schmidt SD, O'Dell S, McDanal C, Feng W, et al. Booster of mRNA-1273
- 396 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies. medRxiv.
- 397 2021:2021.12.15.21267805.

398

Supplementary Material - Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations

402 **Supplementary Table S1.** Comorbidities of study participants (NA: not available; CVD:

403 cardiovascular disease).

404

Sample cohort (n)	Co- morbi- dities (n, %)	CVD (n, %)	Lung disease (n, %)	Diabetes (n, %)	Cancer (n, %)	Immune- supp- ression (n, %)	Hyper- tension (n, %)
two-dose BNT162b 2 T1* (15)	0:9 (64.3) 1:4 (28.6) 2:1 (7.1) >2: 0 (0) 1 NA	0(0)	1 (7.1)	0(0)	0(0)	0 (0)	5 (35.7)
two-dose BNT162b 2 T2* (15)	0: 8 (53.3) 1: 5 (33.3) 2: 2 (13.3) >2: 0 (0)	1 (6.7)	1 (6.7)	0(0)	0(0)	2 (13.3)	5 (33.4)
two-dose mRNA- 1273 (16)	0: 12 (75) 1: 4 (25) 2: 0 (0) >2: 0 (0)	1 (6.3)	1 (6.3)	0 (0)	1 (6.3)	0 (0)	1 (6.3)
first dose AZD1222, second dose mRNA- 1273 (11)	0: 7 (63.6) 1: 3 (27.3) 2: 1 (9.1) >2: 0 (0)	2 (18.2)	0 (0)	0 (0)	0 (0)	0 (0)	3 (27.3)
first dose AZD1222, second dose BNT162b 2 (15)	0: 8 (53.3) 1: 3 (20) 2: 3 (20) >2: 1 (6.7)	1 (6.7)	1 (6.7)	2 (13.3)	1 (6.7)	0 (0)	7 (46.7)
two-dose AZD1222 (14)	0: 7 (50.0) 1: 6 (42.9) 1: 1 (7.1) >2: 0 (0)	0 (0)	0 (0)	2 (14.3)	0 (0)	0 (0)	6 (42.9)
one-dose Ad26.CoV 2.S (11)	0: 7 (63.6) 1: 3 (27.3) 2: 0 (0) >2: 1 (9.1)	1 (9.1)	1 (9.1)	1 (9.1)	0 (0)	1 (9.1)	4 (36.4)

* Two-dose BNT162b2 T1 and two-dose BNT162b2 T2* are paired longitudinal samples.

It is made available under a CC-BY-NC 4.0 International license .

405 **Supplementary Table S2.** Amino acid mutations of Spike proteins used for SARS-CoV-2

406 pseudotype construction compared to the parental strain B.1. Shared mutations among the 407 constructs are highlighted in bold.

408

B.1.351 (Beta) (EPI_ISL_700428)	B.1.617.2 (Delta) (EPI_ISL_1921353)	B.1.1.529 (Omicron) (EPI_ISL_6640919)	
	T19R		
		A67V	
		69-70del	
D80A			
		T95I	
	G142D	G142D	
		143-145del	
	E156G		
	157-158del		
		N211del/L212I	
		Ins214EPE	
242-244del			
R246I			
		G339D	
		S371L	
		S373P	
		S375F	
K417N		K417N	
		N440K	
		G446S	
	L452R		
		S477N	
	T478K	T478K	
E484K		E484A	
		Q493R	
		G496S	
		Q498R	
N501Y		N501Y	
		Y505H	
		T547K	
D614G	D614G	D614G	
		H655Y	
		N679K	
	P681R	P681H	
A701V			
		N764K	
		D796Y	
		N856K	
	D950N		
		Q954H	
		N969K	
		L981F	